JP2022513556A - κオピオイド受容体作動薬の経口製剤 - Google Patents
κオピオイド受容体作動薬の経口製剤 Download PDFInfo
- Publication number
- JP2022513556A JP2022513556A JP2021513853A JP2021513853A JP2022513556A JP 2022513556 A JP2022513556 A JP 2022513556A JP 2021513853 A JP2021513853 A JP 2021513853A JP 2021513853 A JP2021513853 A JP 2021513853A JP 2022513556 A JP2022513556 A JP 2022513556A
- Authority
- JP
- Japan
- Prior art keywords
- phe
- opioid receptor
- chain fatty
- fatty acid
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002632 kappa opiate receptor agonist Substances 0.000 title claims abstract description 87
- 229940126470 kappa opioid receptor agonist Drugs 0.000 title claims abstract description 87
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 239000002775 capsule Substances 0.000 claims abstract description 62
- 150000004667 medium chain fatty acids Chemical group 0.000 claims abstract description 56
- 238000010521 absorption reaction Methods 0.000 claims abstract description 54
- 239000003623 enhancer Substances 0.000 claims abstract description 54
- 150000003839 salts Chemical class 0.000 claims abstract description 51
- 102000048260 kappa Opioid Receptors Human genes 0.000 claims abstract description 47
- 108020001588 κ-opioid receptors Proteins 0.000 claims abstract description 47
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 33
- 229940127557 pharmaceutical product Drugs 0.000 claims abstract description 31
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 26
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 26
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 20
- 229940044601 receptor agonist Drugs 0.000 claims abstract description 18
- 239000000018 receptor agonist Substances 0.000 claims abstract description 18
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 94
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 83
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 62
- 230000000975 bioactive effect Effects 0.000 claims description 50
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 41
- 239000002245 particle Substances 0.000 claims description 27
- 239000000725 suspension Substances 0.000 claims description 26
- 235000000346 sugar Nutrition 0.000 claims description 25
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 21
- KHABBYNLBYZCKP-UHFFFAOYSA-N 4-aminopiperidin-1-ium-4-carboxylate Chemical compound OC(=O)C1(N)CCNCC1 KHABBYNLBYZCKP-UHFFFAOYSA-N 0.000 claims description 17
- 239000003826 tablet Substances 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- 239000011230 binding agent Substances 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000002738 chelating agent Substances 0.000 claims description 5
- FUJLYHJROOYKRA-QGZVFWFLSA-N O-lauroyl-L-carnitine Chemical compound CCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C FUJLYHJROOYKRA-QGZVFWFLSA-N 0.000 claims description 4
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims description 4
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 239000000178 monomer Substances 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- JHLHNYVMZCADTC-LOSJGSFVSA-N asimadoline Chemical compound C([C@@H](N(C)C(=O)C(C=1C=CC=CC=1)C=1C=CC=CC=1)C=1C=CC=CC=1)N1CC[C@H](O)C1 JHLHNYVMZCADTC-LOSJGSFVSA-N 0.000 claims description 2
- 150000001734 carboxylic acid salts Chemical class 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 2
- XGZZHZMWIXFATA-UEZBDDGYSA-N nalfurafine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3N(C)C(=O)\C=C\C1=COC=C1)CN2CC1CC1 XGZZHZMWIXFATA-UEZBDDGYSA-N 0.000 claims description 2
- 229960000441 nalfurafine Drugs 0.000 claims description 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 150000004666 short chain fatty acids Chemical class 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 61
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 44
- 241000124008 Mammalia Species 0.000 abstract description 32
- 201000010099 disease Diseases 0.000 abstract description 32
- 208000003251 Pruritus Diseases 0.000 abstract description 25
- 206010061218 Inflammation Diseases 0.000 abstract description 24
- 230000004054 inflammatory process Effects 0.000 abstract description 24
- 238000000034 method Methods 0.000 abstract description 22
- 238000010586 diagram Methods 0.000 abstract 1
- 229920001542 oligosaccharide Polymers 0.000 abstract 1
- 150000002482 oligosaccharides Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 131
- 108090000765 processed proteins & peptides Proteins 0.000 description 113
- 150000001408 amides Chemical class 0.000 description 78
- 238000009472 formulation Methods 0.000 description 62
- -1 medium-chain fatty acid salt Chemical class 0.000 description 55
- 235000002639 sodium chloride Nutrition 0.000 description 47
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 37
- 150000008574 D-amino acids Chemical class 0.000 description 31
- 229910052799 carbon Inorganic materials 0.000 description 25
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 description 23
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 22
- 229910052757 nitrogen Inorganic materials 0.000 description 22
- 0 CCCC1(CC)[C@@](C)CCC1*C(C)C(*CC)C(C1C2*1)C2C1C(*2)C2C1 Chemical compound CCCC1(CC)[C@@](C)CCC1*C(C)C(*CC)C(C1C2*1)C2C1C(*2)C2C1 0.000 description 21
- 125000000623 heterocyclic group Chemical group 0.000 description 21
- 235000014113 dietary fatty acids Nutrition 0.000 description 20
- 239000000194 fatty acid Substances 0.000 description 20
- 229930195729 fatty acid Natural products 0.000 description 20
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 19
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 18
- 206010021036 Hyponatraemia Diseases 0.000 description 18
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 17
- 125000000217 alkyl group Chemical group 0.000 description 16
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 16
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
- 239000002253 acid Substances 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 150000004665 fatty acids Chemical class 0.000 description 15
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 14
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 150000002016 disaccharides Chemical class 0.000 description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 12
- 206010030113 Oedema Diseases 0.000 description 11
- 150000001721 carbon Chemical group 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 10
- 229930182832 D-phenylalanine Natural products 0.000 description 10
- 208000004454 Hyperalgesia Diseases 0.000 description 10
- 208000035154 Hyperesthesia Diseases 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 9
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 9
- 229910052708 sodium Inorganic materials 0.000 description 9
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 8
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- 208000008384 ileus Diseases 0.000 description 8
- 229960002446 octanoic acid Drugs 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 8
- 229960002429 proline Drugs 0.000 description 8
- 125000006413 ring segment Chemical group 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 229930028154 D-arginine Natural products 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 108010004977 Vasopressins Proteins 0.000 description 7
- 102000002852 Vasopressins Human genes 0.000 description 7
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 230000004770 neurodegeneration Effects 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 229960003726 vasopressin Drugs 0.000 description 7
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 6
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 6
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 6
- 208000018522 Gastrointestinal disease Diseases 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 6
- 201000007100 Pharyngitis Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 201000008937 atopic dermatitis Diseases 0.000 description 6
- 210000000941 bile Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 208000002551 irritable bowel syndrome Diseases 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 229930182819 D-leucine Natural products 0.000 description 5
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 5
- LRQKBLKVPFOOQJ-RXMQYKEDSA-N D-norleucine Chemical compound CCCC[C@@H](N)C(O)=O LRQKBLKVPFOOQJ-RXMQYKEDSA-N 0.000 description 5
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 5
- 206010012438 Dermatitis atopic Diseases 0.000 description 5
- 208000010412 Glaucoma Diseases 0.000 description 5
- 208000006877 Insect Bites and Stings Diseases 0.000 description 5
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 235000015165 citric acid Nutrition 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- 208000004296 neuralgia Diseases 0.000 description 5
- 208000021722 neuropathic pain Diseases 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 4
- JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical compound C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 description 4
- 208000034656 Contusions Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 206010012442 Dermatitis contact Diseases 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 4
- 206010015958 Eye pain Diseases 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- 208000001294 Nociceptive Pain Diseases 0.000 description 4
- 208000004550 Postoperative Pain Diseases 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 229940124532 absorption promoter Drugs 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 150000001294 alanine derivatives Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 238000012321 colectomy Methods 0.000 description 4
- 208000010247 contact dermatitis Diseases 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- FXHCFPUEIDRTMR-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;chloride Chemical compound Cl.C1=CC=C2CNC(C(=O)O)CC2=C1 FXHCFPUEIDRTMR-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 235000013772 propylene glycol Nutrition 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000012453 solvate Chemical class 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000009935 visceral pain Diseases 0.000 description 4
- OKRURFWORCCNOU-UHFFFAOYSA-N 1,2-dihydroimidazole-3-carboximidamide Chemical class NC(=N)N1CNC=C1 OKRURFWORCCNOU-UHFFFAOYSA-N 0.000 description 3
- PECYZEOJVXMISF-UWTATZPHSA-N 3-amino-D-alanine Chemical compound NC[C@@H](N)C(O)=O PECYZEOJVXMISF-UWTATZPHSA-N 0.000 description 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 206010014020 Ear pain Diseases 0.000 description 3
- 201000009273 Endometriosis Diseases 0.000 description 3
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 3
- 206010015943 Eye inflammation Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 208000007514 Herpes zoster Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 201000008197 Laryngitis Diseases 0.000 description 3
- 206010029148 Nephrolithiasis Diseases 0.000 description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 description 3
- 208000030053 Opioid-Induced Constipation Diseases 0.000 description 3
- 208000005141 Otitis Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010054048 Postoperative ileus Diseases 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 206010039705 Scleritis Diseases 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 206010046823 Uterine spasm Diseases 0.000 description 3
- 206010048937 Vaginal lesion Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000002192 cholecystectomy Methods 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 238000002574 cystoscopy Methods 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002497 edematous effect Effects 0.000 description 3
- 230000002357 endometrial effect Effects 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 150000002303 glucose derivatives Chemical class 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 238000009802 hysterectomy Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000002357 laparoscopic surgery Methods 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002175 menstrual effect Effects 0.000 description 3
- 208000037819 metastatic cancer Diseases 0.000 description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 229960003104 ornithine Drugs 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 231100000019 skin ulcer Toxicity 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 2
- IFPQOXNWLSRZKX-GSVOUGTGSA-N (2r)-2-amino-4-(diaminomethylideneamino)butanoic acid Chemical compound OC(=O)[C@H](N)CCNC(N)=N IFPQOXNWLSRZKX-GSVOUGTGSA-N 0.000 description 2
- QUOGESRFPZDMMT-RXMQYKEDSA-N (2r)-2-amino-6-(diaminomethylideneamino)hexanoic acid Chemical compound OC(=O)[C@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-RXMQYKEDSA-N 0.000 description 2
- LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- FSUZNMAWSKOCOZ-UHFFFAOYSA-N 3-carbamimidoyl-1,4-oxazepane-4-carboxamide Chemical compound C(N)(=N)C1N(CCCOC1)C(=O)N FSUZNMAWSKOCOZ-UHFFFAOYSA-N 0.000 description 2
- 125000001963 4 membered heterocyclic group Chemical group 0.000 description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 2
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 2
- 150000008541 D-alanines Chemical class 0.000 description 2
- 229930182820 D-proline Natural products 0.000 description 2
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010052138 Ear pruritus Diseases 0.000 description 2
- 206010052140 Eye pruritus Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 241001272567 Hominoidea Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000019025 Hypokalemia Diseases 0.000 description 2
- 206010021137 Hypovolaemia Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 206010028116 Mucosal inflammation Diseases 0.000 description 2
- 201000010927 Mucositis Diseases 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000000491 Tendinopathy Diseases 0.000 description 2
- 206010043255 Tendonitis Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000002052 colonoscopy Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 230000009519 contusion Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 210000005095 gastrointestinal system Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 201000008284 inappropriate ADH syndrome Diseases 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 208000024896 potassium deficiency disease Diseases 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 201000004415 tendinitis Diseases 0.000 description 2
- 239000003451 thiazide diuretic agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 description 2
- 238000009810 tubal ligation Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- WDDUMSKLWZBIJS-HWVUQVAQSA-N (2r)-1-[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCN=C(N)N)C(=O)N1[C@H](CCC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 WDDUMSKLWZBIJS-HWVUQVAQSA-N 0.000 description 1
- UJOQOPBFLFQOJJ-HXUWFJFHSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-methylhexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@H](CCC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UJOQOPBFLFQOJJ-HXUWFJFHSA-N 0.000 description 1
- KUNFMZSTKSLIEY-NWKMIUOTSA-N (2r)-2-azanyl-3-phenyl-propanoic acid Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1.OC(=O)[C@H](N)CC1=CC=CC=C1 KUNFMZSTKSLIEY-NWKMIUOTSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical compound C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 description 1
- NANQJUFFKXWVJR-UHFFFAOYSA-N 1-(benzenesulfonyl)piperazine Chemical compound C=1C=CC=CC=1S(=O)(=O)N1CCNCC1 NANQJUFFKXWVJR-UHFFFAOYSA-N 0.000 description 1
- ZZAKLGGGMWORRT-UHFFFAOYSA-N 1-methylsulfonylpiperazine Chemical compound CS(=O)(=O)N1CCNCC1 ZZAKLGGGMWORRT-UHFFFAOYSA-N 0.000 description 1
- HTQWGIHCFPWKAS-UHFFFAOYSA-N 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1CNCCC11C(=O)NCN1C1=CC=CC=C1 HTQWGIHCFPWKAS-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- FCQHYITXTSIWDB-UHFFFAOYSA-N 2-(4-azaniumylpiperidin-1-yl)acetate Chemical compound NC1CCN(CC(O)=O)CC1 FCQHYITXTSIWDB-UHFFFAOYSA-N 0.000 description 1
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 240000004731 Acer pseudoplatanus Species 0.000 description 1
- 235000002754 Acer pseudoplatanus Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010068172 Anal pruritus Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010004637 Bile duct stone Diseases 0.000 description 1
- 208000000003 Breakthrough pain Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- DTLURYNMLRGWJA-DOKYCRFOSA-N C/C(/C=C1/NC(CN)=O)=C\CC/C=N\[NH+]1[O-] Chemical compound C/C(/C=C1/NC(CN)=O)=C\CC/C=N\[NH+]1[O-] DTLURYNMLRGWJA-DOKYCRFOSA-N 0.000 description 1
- VWDYQOCSMBDKGA-FPLPWBNLSA-N CC(/C=C\C1=CC=CCC1)O Chemical compound CC(/C=C\C1=CC=CCC1)O VWDYQOCSMBDKGA-FPLPWBNLSA-N 0.000 description 1
- MBQDNGLFROYEEC-IBVNLNJUSA-N CC(C)CN([C@H](CCCCNC(N)N)C(N(CCC1)CCC1(C1)C1C(N)N)=O)C(CNC([C@@H](Cc1ccccc1)NC([C@@H](Cc1ccccc1)N)=O)=O)=O Chemical compound CC(C)CN([C@H](CCCCNC(N)N)C(N(CCC1)CCC1(C1)C1C(N)N)=O)C(CNC([C@@H](Cc1ccccc1)NC([C@@H](Cc1ccccc1)N)=O)=O)=O MBQDNGLFROYEEC-IBVNLNJUSA-N 0.000 description 1
- QXMNDNXUWOBHPN-MITVMGGRSA-N CC(C)C[C@H](C(N[C@H](CCCCN)C(N(CC1)CCC1N(C(C1)O)c2c1cccc2)=O)=O)NC([C@@H](Cc1ccccc1)NC([C@@H](Cc1ccccc1)N)=O)=O Chemical compound CC(C)C[C@H](C(N[C@H](CCCCN)C(N(CC1)CCC1N(C(C1)O)c2c1cccc2)=O)=O)NC([C@@H](Cc1ccccc1)NC([C@@H](Cc1ccccc1)N)=O)=O QXMNDNXUWOBHPN-MITVMGGRSA-N 0.000 description 1
- YKRHPXOABOFQCH-OMRVPHBLSA-N CC(C)C[C@H](C(N[C@H](CCCCN)C(N1CCN(C)CC1)=O)=O)NC([C@@H](Cc1ccccc1)NC([C@@H](Cc1ccccc1)N)=O)=O Chemical compound CC(C)C[C@H](C(N[C@H](CCCCN)C(N1CCN(C)CC1)=O)=O)NC([C@@H](Cc1ccccc1)NC([C@@H](Cc1ccccc1)N)=O)=O YKRHPXOABOFQCH-OMRVPHBLSA-N 0.000 description 1
- DFHIXHHKTWGFPI-LPYGTTGFSA-N CC(C)C[C@H](C(N[C@H](CCCCNC)C(N(CC1)CCN1C(c1ccccc1)=O)=O)=O)NC([C@@H](Cc1ccccc1)NC([C@@H](Cc1ccccc1)N)=O)=O Chemical compound CC(C)C[C@H](C(N[C@H](CCCCNC)C(N(CC1)CCN1C(c1ccccc1)=O)=O)=O)NC([C@@H](Cc1ccccc1)NC([C@@H](Cc1ccccc1)N)=O)=O DFHIXHHKTWGFPI-LPYGTTGFSA-N 0.000 description 1
- JYPSQVCUXJPOSG-HVFAODJTSA-N CC(C)C[C@H](C(N[C@H](CCCN)C(N[C@@H](C1)CN[C@@H]1C(O)=O)=O)=O)NC([C@@H](C/C(/C)=C/C=C\C)NC([C@@H](Cc1ccccc1)N)=O)=O Chemical compound CC(C)C[C@H](C(N[C@H](CCCN)C(N[C@@H](C1)CN[C@@H]1C(O)=O)=O)=O)NC([C@@H](C/C(/C)=C/C=C\C)NC([C@@H](Cc1ccccc1)N)=O)=O JYPSQVCUXJPOSG-HVFAODJTSA-N 0.000 description 1
- HVVKFZDATUKGCW-CHZFIGIYSA-N CC(C)C[C@H](C(N[C@H](CCCNC(C)C)C(N1CCOCCC1)=O)=O)NC([C@@H](Cc1ccccc1)N(C(CN)O)c1ccccc1C)=O Chemical compound CC(C)C[C@H](C(N[C@H](CCCNC(C)C)C(N1CCOCCC1)=O)=O)NC([C@@H](Cc1ccccc1)N(C(CN)O)c1ccccc1C)=O HVVKFZDATUKGCW-CHZFIGIYSA-N 0.000 description 1
- SMWMBVZZHPXBCV-JHRLVUGGSA-N CCCC[C@@H](N)C(O)=O.OC(=O)[C@H](N)CCCNC(N)=N Chemical compound CCCC[C@@H](N)C(O)=O.OC(=O)[C@H](N)CCCNC(N)=N SMWMBVZZHPXBCV-JHRLVUGGSA-N 0.000 description 1
- XCHCHSXNYFSMJH-BIYDSLDMSA-N CCCC[C@H](C(N[C@H](CNC(N)=N)C(N(CCC1)CCN1C(N)=N)=O)=O)NC([C@@H](Cc1ccccc1)NC([C@@H](Cc1ccccc1)N)=O)=O Chemical compound CCCC[C@H](C(N[C@H](CNC(N)=N)C(N(CCC1)CCN1C(N)=N)=O)=O)NC([C@@H](Cc1ccccc1)NC([C@@H](Cc1ccccc1)N)=O)=O XCHCHSXNYFSMJH-BIYDSLDMSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229930195711 D-Serine Natural products 0.000 description 1
- 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 description 1
- 229930182845 D-isoleucine Natural products 0.000 description 1
- 229930182818 D-methionine Natural products 0.000 description 1
- 125000001711 D-phenylalanine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000180 D-prolyl group Chemical group N1[C@@H](C(=O)*)CCC1 0.000 description 1
- 229930182822 D-threonine Natural products 0.000 description 1
- 229930182827 D-tryptophan Natural products 0.000 description 1
- 229930195709 D-tyrosine Natural products 0.000 description 1
- 229930182831 D-valine Natural products 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 208000022555 Genital disease Diseases 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- HDIFHQMREAYYJW-XGXNLDPDSA-N Glyceryl Ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-XGXNLDPDSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical compound NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 description 1
- 206010024652 Liver abscess Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- PMHLOCAVHRSGFK-ZYTCOCFOSA-N N[C@H](CCCN)C(=O)O.N[C@H](CC(C)C)C(=O)O Chemical compound N[C@H](CCCN)C(=O)O.N[C@H](CC(C)C)C(=O)O PMHLOCAVHRSGFK-ZYTCOCFOSA-N 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 206010062065 Perforated ulcer Diseases 0.000 description 1
- 241000158136 Phrynosoma douglasii Species 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 235000006485 Platanus occidentalis Nutrition 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010063438 Pruritus allergic Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010058156 Reperfusion arrhythmia Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 206010041955 Stasis dermatitis Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000032159 Vaginal inflammation Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000004136 Vasopressin Receptors Human genes 0.000 description 1
- 108090000643 Vasopressin Receptors Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- MZWHRPKAHCWTOI-KGURMGBCSA-N acetic acid 4-amino-1-[(2R)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound CC(O)=O.CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O MZWHRPKAHCWTOI-KGURMGBCSA-N 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000010550 acute laryngitis Diseases 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 208000025222 central nervous system infectious disease Diseases 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229950003869 difelikefalin Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000011863 diuretic therapy Methods 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940116338 glyceryl ricinoleate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004970 halomethyl group Chemical group 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000027701 hepatic abscess Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 201000007272 intracranial sinus thrombosis Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000000412 mechanoreceptor Anatomy 0.000 description 1
- 108091008704 mechanoreceptors Proteins 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- NQZDGTYTTVHKPE-UHFFFAOYSA-N n,n-dimethylpiperazine-1-sulfonamide Chemical compound CN(C)S(=O)(=O)N1CCNCC1 NQZDGTYTTVHKPE-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 229940023486 oral product Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940051877 other opioids in atc Drugs 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- OJTDGPLHRSZIAV-UHFFFAOYSA-N propane-1,2-diol Chemical compound CC(O)CO.CC(O)CO OJTDGPLHRSZIAV-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940116422 propylene glycol dicaprate Drugs 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- GZRKXKUVVPSREJ-UHFFFAOYSA-N pyridinylpiperazine Chemical compound C1CNCCN1C1=CC=CC=N1 GZRKXKUVVPSREJ-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本発明は、治療薬の経口送達のための製剤に関する。製剤は、活性医薬成分(API)の形態での治療薬、中鎖脂肪酸又は中鎖脂肪酸の塩及び中鎖脂肪酸グリセリドを含む。好適な活性医薬成分は、D-アミノ酸ペプチドアミドなどのκオピオイド受容体作動薬を含む。
κオピオイド受容体作動薬は、κオピオイド受容体関連疾患及び病態の予防又は治療を有効にするための効率的送達及び十分な生物学的利用率を意図した新規製剤への需要に至る、固有の物理化学的特性を有する治療薬の新規クラスである。新規のκは、Schteingart et al.に交付された米国特許第7,402,564号、米国特許第7,713,937号及び米国特許第7,842,662号に開示された合成ペプチドアミド並びにアシマドリン(N-[(1S)-2-[(3S)-3-ヒドロキシピロリジン-1-イル]-1-フェニルエチル]-N-メチル-2,2-ジフェニルアセトアミド)及びナルフラフィン((2E)-N-[(5α,6β)-17-(シクロプロピルメチル)-3,14-ジヒドロキシ-4,5-エポキシモルフィナン-6-イル]-3-(3-フリル)-N-メチルアクリルアミド)を含む。
本発明は、κオピオイド受容体作動薬及び吸収促進剤を含む治療薬の経口送達のための製剤を提供する。一実施形態では、本発明の製剤は、中鎖脂肪酸又は中鎖脂肪酸の塩及び中鎖脂肪酸グリセリドを、κオピオイド受容体作動薬の胃腸系からの取り込みを最適化し、それによりその生物学的活性を増強するのに適した吸収促進剤として含む。ある代替例では、本発明は、中鎖脂肪酸又は中鎖脂肪酸の塩を含み、且つ中鎖脂肪酸グリセリドを含まない経口製剤を提供する。別の代替例では、本発明は、中鎖脂肪酸グリセリドを含み、且つ中鎖脂肪酸又は中鎖脂肪酸の塩を含まない経口製剤を提供する。
Xaa1-Xaa2-Xaa3-Xaa4-(G) 式I
の構造を有する。
D-Phe-D-Phe-D-Leu-D-Lys-[ω(4-アミノピペリジン-4-カルボン酸)]-OH
の構造を有するCR845である。
一実施形態では、本発明の経口製剤は、ペプチド及び少なくとも1つの吸収促進剤を含む治療薬を含み、吸収促進剤は、中鎖脂肪酸又は中鎖脂肪酸の塩及び中鎖脂肪酸グリセリドを含み、中鎖脂肪酸又は中鎖脂肪酸の塩は、カプリン酸又はカプリン酸の塩を含む。
であり、且つXaa1は、D-Pheであり、Xaa2は、D-Pheであり、Xaa3は、D-Leuであり、Xaa4は、ε(B)2D-Lys又はδ-(B)2D-Ornであり、ここで、(B)は、-H、メチル又はイソプロピルであり;さらに、ここで、Wは、ヌルであり、Y及びZ含有環部分は、6又は7員環であり、Yは、窒素原子であり、eは、0であり、R1は、-NH2、アミジノ、C1~C3アルキル、C1~C3アルキル置換アミジノ、ジヒドロイミダゾール、D-Pro又はD-Proアミドであり、且つR2は、H又は-COOHである。
を有し、ここで、Gは、
であり、且つbは、0であり、且つYは、炭素原子である。別の実施形態では、bは、1又は2であり、且つYは、窒素原子である。本発明の特定の態様では、bは、2である。
化合物(1)~(103)として列挙されるD-アミノ酸ペプチドアミドの以下のリストは、本発明の製剤において使用可能である。
D-アミノ酸ペプチドアミド
実施例(1)~(103):
化合物(1):D-Phe-D-Phe-D-Leu-(ε-Me)D-Lys-[4-アミジノホモピペラジンアミド]:
化合物(2):D-Phe-D-Phe-D-Leu-D-Lys-[ω(4-アミノピペリジン-4-カルボン酸)]-OH:
化合物(3):D-Phe-D-Phe-D-Leu-(ε-Me)D-Lys-[ω(4-アミノピペリジン-4-カルボン酸)]-OH:
化合物(4):D-Phe-D-Phe-D-Leu-D-Lys-[N-(4-ピペリジニル)-L-プロリン]-OH:
化合物(5):D-Phe-D-Phe-D-Leu-D-Har-[N-(4-ピペリジニル)-L-プロリン]-OH:
化合物(6):D-Phe-D-Phe-D-Leu-(ε-Me)D-Lys-[N-(4-ピペリジニル)-L-プロリン]-OH:
化合物(7):D-Phe-D-Phe-D-Leu-D-Arg-[ホモピペラジンアミド]:
化合物(8):D-Phe-D-Phe-D-Leu-D-Har-[ω(4-アミノピペリジン-4-カルボン酸)]-OH:
化合物(9):D-Phe-D-Phe-D-Leu-(ε-iPr)D-Lys-[ω(4-アミノピペリジン-4-カルボン酸)]-OH:
化合物(10):D-Phe-D-Phe-D-Leu-(β-アミジノ)D-Dap-[ω(4-アミノピペリジン-4-カルボン酸)]-OH:
化合物(11):D-Phe-D-Phe-D-Leu-D-Nar-[ω(4-アミノピペリジン-4-カルボン酸)]-OH:
化合物(12):D-Phe-D-Phe-D-Leu-D-Dbu-[N-(4-ピペリジニル)-L-プロリン]-OH:
化合物(13):D-Phe-D-Phe-D-Leu-D-Nar-[N-(4-ピペリジニル)-L-プロリン]-OH:
化合物(14):D-Phe-D-Phe-D-Leu-D-Dap(アミジノ)-[N-(4-ピペリジニル)-L-プロリン]-OH:
化合物(15):D-Phe-D-Phe-D-Leu-D-Lys-[4-アミジノホモピペラジンアミド]:
化合物(16):D-Phe-D-Phe-D-Leu-D-Har-[4-アミジノホモピペラジンアミド]:
化合物(17):D-Phe-D-Phe-D-Leu-(ε-iPr)D-Lys-[4-アミジノホモ-ピペラジンアミド]:
化合物(18):D-Phe-D-Phe-D-Leu-(β-アミジノ)D-Dap-[4-アミジノホモピペラジンアミド]:
化合物(19):D-Phe-D-Phe-D-Nle-(β-アミジノ)D-Dap-[4-アミジノホモピペラジンアミド]:
化合物(20):D-Phe-D-Phe-D-Leu-(β-アミジノ)D-Dap-[ホモピペラジンアミド]:
化合物(21):D-Phe-D-Phe-D-Nle-(β-アミジノ)D-Dap-[ホモピペラジンアミド]:
化合物(22):D-Phe-D-Phe-D-Leu-D-Dbu-[4-アミジノホモピペラジンアミド]:
化合物(23):D-Phe-D-Phe-D-Leu-D-Nar-[4-アミジノホモピペラジンアミド]:
化合物(24):D-Phe-D-Phe-D-Leu-D-Arg-[4-アミジノホモピペラジンアミド]:
化合物(25):D-Phe-D-Phe-D-Leu-D-Lys-[2,8-ジアザスピロ[4,5]デカン-1-オンアミド]:
化合物(26):D-Phe-D-Phe-D-Leu-D-Lys-[2-メチル-2,8-ジアザスピロ[4,5]デカン-1-オンアミド]:
化合物(27):D-Phe-D-Phe-D-Leu-D-Lys-[1,3,8-トリアザスピロ[4,5]デカン-2,4-ジオンアミド]:
化合物(28):D-Phe-D-Phe-D-Leu-D-Lys-[5-クロロ-1-(ピペリジン-4-イル)-1H-ベンゾ[d]イミダゾール-2(3)H-オンアミド]:
化合物(29):D-Phe-D-Phe-D-Leu-D-Lys-[モルホリノ(ピペリジン-4-イル)メタノンアミド]:
化合物(30):D-Phe-D-Phe-D-Leu-D-Lys-[4-フェニル-1-(ピペリジン-イル-1H-イミダゾール-2(3H)-オンアミド]:
化合物(31):D-Phe-D-Phe-D-Leu-D-Lys-[4-(3,5-ジメチル-4H-1,2,4-トリアゾール-4-イル)ピペリジンアミド]:
化合物(32):D-Phe-D-Phe-D-Leu-D-Lys-[1-(ピペリジン-4-イル)インドリン-2-オンアミド]:
化合物(33):D-Phe-D-Phe-D-Leu-D-Lys-[1-フェニル-1,3,8-トリアザスピロ[4.5]デカン-4-オンアミド]:
化合物(34):D-Phe-D-Phe-D-Leu-D-Lys-[イミダゾ[1,2-a]ピリジン-2-イルメチルアミド]:
化合物(35)D-Phe-D-Phe-D-Leu-D-Lys-[(5-メチルピラジン-2-イル)メチルアミド]:
化合物(36):D-Phe-D-Phe-D-Leu-D-Lys-[1-(ピペリジン-4-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オンアミド]:
化合物(37):D-Phe-D-Phe-D-Leu-D-Lys-[4,5,6,7-テトラヒドロ-1H-ピラゾロ[4,3-c]ピリジンアミド]:
化合物(38):D-Phe-D-Phe-D-Leu-D-Orn-[4-(2-アミノエチル)-1-カルボキシメチル-ピペラジン]-OH:
化合物(39)D-Phe-D-Phe-D-Leu-D-Orn-[4-カルボキシメチル-ピペリジン]-OH:
化合物(40)D-Phe-D-Phe-D-Nle-D-Arg-D-Pro-OH:
化合物(41)D-Phe-D-Phe-D-Leu-D-Orn-[(2S,4R)-4-アミノ-ピロリジン-2-カルボン酸]-OH:
化合物(42)D-Phe-D-Phe-D-Leu-D-Orn-[(2S,4S)-4-アミノ-ピロリジン-2-カルボン酸]-OH:
化合物(43)D-Phe-D-Phe-D-Leu-D-Orn-[ω(4-アミノピペリジン-4-カルボン酸)]-OH:
化合物(44)D-Phe-D-Phe-D-Leu-D-Orn-[ω(D/L-2-アミノ-3-(4-N-ピペリジニル)プロピオン酸)]-OH:
化合物(45)D-Phe-D-Phe-D-Leu-D-Orn-[ω(D/L-4-ピペラジン-2-カルボン酸)]-OH:
化合物(46)D-Phe-D-Phe-D-Leu-D-Orn-[イソニペコチン酸]-OH:
化合物(47)D-Phe-D-Phe-D-Leu-D-Orn-[N-(4-ピペリジニル)-L-プロリン]-OH:
化合物(48)D-Phe-D-Phe-D-Leu-D-Orn-[4-(4-ピペリジニル)-ブタン酸]-OH:
化合物(49)D-Phe-D-Phe-D-Leu-D-Orn-[4-(2-アミノエチル)-1-カルボキシメチル-ピペラジン]-NH2:
化合物(50)D-Phe-D-Phe-D-Leu-D-Orn-[N-(4-ピペリジニル)-L-プロリン]-NH2:
化合物(51)D-Phe-D-Phe-D-Leu-D-Orn-[4-アミノ-1-カルボキシメチル-ピペリジン]-NH2:
化合物(52)D-Phe-D-Phe-D-Leu-D-Orn-[4-(N-メチル)アミジノ-ホモピペラジンアミド]:
化合物(53)D-Phe-D-Phe-D-Leu-D-Orn-[4-アミジノホモピペラジンアミド]:
化合物(54)D-Phe-D-Phe-D-Leu-D-Orn-[4-(4,5-ジヒドロ-1H-イミダゾール-2-イル)ホモピペラジンアミド]:
化合物(55)D-Phe-D-Phe-D-Leu-D-Orn-[4-エチルホモピペラジンアミド]:
化合物(56)D-Phe-D-Phe-D-Leu-D-Orn-[ホモピペラジンアミド]:
化合物(57)D-Phe-D-Phe-D-Leu-(δ-Me)D-Orn-[4-アミジノホモピペラジンアミド]:
化合物(58)D-Phe-D-Phe-D-Leu-(δ-iPr)D-Orn-[ω(4-アミノピペリジン-4-カルボン酸)]-OH:
化合物(59)D-Phe-D-Phe-D-Leu-(δ-iPr)D-Orn-[4-アミジノホモピペラジンアミド]:
化合物(60)D-Phe-D-Phe-D-Leu-(δ-Me)D-Orn-[ホモピペラジンアミド]:
化合物(61)D-Phe-D-Phe-D-Leu-(δ-iPr)D-Orn-[ホモピペラジンアミド]:
化合物(62):D-Phe-D-Phe-D-Leu-D-Lys-[1,3-ジオキソラン-2-イル)メタンアミンアミド]:
化合物(63):D-Phe-D-Phe-D-Leu-D-Lys-[2-(ピペラジン-1-イル)ピリミジンアミド]:
化合物(64):D-Phe-D-Phe-D-Leu-D-Lys-[2-(ピペラジン-1-イル)ピラジンアミド]:
化合物(65):D-Phe-D-Phe-D-Leu-D-Lys-[1-(ピリジン-2-イル)ピペラジンアミド]:
化合物(66):D-Phe-D-Phe-D-Leu-D-Lys-[2-(ピペラジン-1-イル)チアゾールアミド]:
化合物(67):D-Phe-D-Phe-D-Leu-D-Lys-[N,N-ジメチルピペラジン-1-スルホンアミドアミド]:
化合物(68):D-Phe-D-Phe-D-Leu-D-Lys-[1-(メチルスルホニル)ピペラジンアミド]:
化合物(69):D-Phe-D-Phe-D-Leu-D-Lys-[1-(フェニルスルホニル)ピペラジンアミド]:
化合物(70):D-Phe-D-Phe-D-Leu-D-Lys-[フェニル(ピペラジン-1-イル)メタノンアミド]:
化合物(71):D-Phe-D-Phe-D-Leu-D-Lys-[チオールモルホリン-1,1-ジオキシドアミド]:
化合物(72):D-Phe-D-Phe-D-Leu-D-Lys-[6-トリフルオロメチル-3-アミノメチルピリジンアミド]:
化合物(73):D-Phe-D-Phe-D-Leu-D-Lys-N-メチル-1-(テトラヒドロ-2H-ピラン-4-イル)メタンアミンアミド:
化合物(74):D-Phe-D-Phe-D-Leu-D-Lys-[5-(アミノメチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オンアミド]:
化合物(75):D-Phe-D-Phe-D-Leu-D-Lys-N-(チアゾール-2-イルメチル)アミド:
化合物(76):
化合物(77):
化合物(78):
化合物(79):
化合物(80):
化合物(81):
化合物(82):
化合物(83):
化合物(84):
化合物(85):
化合物(86):1N,4N-ビス-[D-Phe-D-Phe-D-Leu-(iPr)D-Orn]-4-アミノ-4-カルボキシル-ピペリジン
化合物(87):1N,4N-ビス-[D-Phe-D-Phe-D-Leu-D-Dap(アミジノ)]-4-アミノ-4-カルボキシピペリジン
化合物(88):1N,4N-ビス-(D-Phe-D-Phe-D-Leu-D-Nar)-4-アミノ-4-カルボキシピペリジン
化合物(89):
化合物(90)D-Phe-D-Phe-D-Leu-D-Orn-[R/S-2-カルボキシモルホリン]-OH:
化合物(91)D-Phe-D-Phe-D-Leu-D-Orn-[R/S-2-カルボキシチオモルホリン]-OH:
化合物(92)D-Phe-D-Phe-D-Leu-D-Orn-N(ホモモルホリン):
化合物(93)D-Phe-D-Phe-D-Leu-D-Orn-N(ホモチオモルホリン):
化合物(94)D-Phe-D-Phe-D-Leu-D-Dap(アミジノ)-[ホモモルホリンアミド]:
化合物(95)D-Phe-D-Phe-D-Leu-D-Dap(アミジノ)-[ホモチオモルホリンアミド]:
化合物(96)D-Phe-D-Phe-D-Nle-D-Dap(アミジノ)-[ホモモルホリンアミド]:
化合物(97)D-Phe-D-Phe-D-Nle-D-Dap(アミジノ)-[ホモチオモルホリンアミド]:
化合物(98)D-Phe-D-Phe-D-Leu-D-Arg-[ホモモルホリンアミド]:
化合物(99)D-Phe-D-Phe-D-Leu-D-Arg-[ホモチオピペラジンアミド]:
化合物(100)D-Phe-D-Phe-D-Leu-D-Orn(Me)-[ホモモルホリンアミド]:
化合物(101)D-Phe-D-Phe-D-Leu-D-Orn(Me)-[ホモチオモルホリンアミド]:
化合物(102)D-Phe-D-Phe-D-Leu-D-Orn(iPr)-[ホモモルホリンアミド]:
化合物(103)D-Phe-D-Phe-D-Leu-D-Orn(iPr)-[ホモチオモルホリンアミド]:
化合物(104): β-tert-Bu-D-Ala-D-Phe-D-Leu-D-Lys-[ω(4-アミノピペリジン-4-カルボン酸)]-OH:
化合物(105): D-tert-Leu-D-Phe-D-Leu-D-Lys-[ω(4-アミノピペリジン-4-カルボン酸)]-OH:
Miglyol(登録商標)812N(44.750g)を50mlのガラスビーカーに添加した。次に、5.00gのカプリン酸を秤量し、0.5インチの撹拌棒を用いて磁気撹拌プレート上で撹拌しながら、Miglyol(登録商標)に添加した。混合物を穏やかな速度で継続的に撹拌した。0.25gのCR845を秤量し(ペプチド含量について調節し)、カプリン酸/Miglyol(登録商標)溶液に、均一に分散された懸濁液を生成するように混合しながら添加した。以下のように実施したカプセル充填プロセスの全体を通して混合を500rpmで維持した。
アセトンNF(888mL)を測定し、1Lのビーカーに注ぎ、撹拌を開始した。穏やかなボルテックスが達成されると、120gのEudragit(登録商標)L100-55を混合しながらアセトンに添加した。次に、12gのクエン酸トリエチルUSPをアセトン/Eudragit(登録商標)L100-55に添加後、19.2gの水USPをアセトン/Eudragit(登録商標)L100-55/クエン酸トリエチルに、溶液が清澄になるまで継続的に撹拌しながら添加した。次に、溶液を1Lの血清ボトルに移し、キャッピングした。
コーティング溶液(200g)をProCoaterカプセル充填剤のためのコーティングパンに移し、製造業者のマニュアル中の使用説明書に従い、充填カプセルの本体をコーティング溶液中のプレートに浸漬し、除去し、回転させた。コーティングされたカプセルを有するプレートをProCoaterカプセル充填剤の乾燥スタンドに置いて、最低25分間乾燥させておいた。ProCoaterマニュアルの指示に従い、カプセルホルダーを、カプセルキャップを曝露させるように調整した。製造業者の使用説明書に従い、カプセルの各々のキャップをコーティング溶液中の各プレートに浸漬し、除去し、回転させた。次に、コーティングされたカプセルを有するプレートをProCoaterカプセル充填剤の乾燥スタンドに置いて、最低25分間乾燥させておいた。次に、追加的なコーティング溶液をコーティングパンに添加して適切な体積を維持し、上記ステップを繰り返し、カプセルを再コーティングした。
Miglyol(登録商標)(34.75g)及びカプリン酸(15.0g)を50mlのガラスビーカーに、清澄な溶液が得られるまで撹拌しながら添加した。CR845(0.25g)をカプリン酸/Miglyol(登録商標)溶液に、均一に分散された懸濁液を生成するように混合しながら添加した。カプセルプレートのセットアップ、1gの30%カプリン酸/Miglyol(登録商標)溶液に懸濁した5mgのCR845のカプセル充填及び腸溶コーティング材料の適用を上記のように実施した。
カプセル内において、試験製剤を単回用量で経口送達した。投与直前にカプセルを逆浸透水で潤滑した。投与後の嚥下反射を刺激するため、動物を首沿いに軽くたたいた。投与直後、5~10mLの逆浸透水を動物に与えた。カプセルが嚥下されたことを確認するため、水を流した後、口腔を検査した。
図1は、上記のように調製した腸溶コーティングされたサイズ2のHPMCカプセルで送達される製剤の各々について動物8匹のコホートで測定したCR845.HCl酸性塩の生物学的利用率を示す。プロトタイプ製剤1の各カプセルは、1.6mgのスプレー乾燥されたCR845、90%Miglyol、10%カプリン酸ナトリウムを含有した。プロトタイプ製剤2の各カプセルは、1.6mgのスプレー乾燥されたCR845、90%Miglyol、10%カプリン酸を含有した。プロトタイプ製剤3の各カプセルは、1.6mgのスプレー乾燥されたCR845、70%Miglyol、30%カプリン酸を含有した。プロトタイプ製剤4の各カプセルは、1.6mgの結晶化されたCR845、90%Miglyol、10%カプリン酸ナトリウムを含有した。生物学的利用率(%f)は、同じ用量の静脈内送達後に認められた総CR845 AUCと比較しての、(曲線下面積:AUCから計算された)認められたCR845のパーセントとして表す。イヌ36匹を用いる5つの別々の試験からの複合IVデータを平均化し、生物学的利用率の計算に使用した。10kgのイヌに0.029±0.007mg/kgの平均用量を投与し、平均生物学的利用率を100%に設定した。認められたavg.Cmaxは、比較目的として163.1±39.2であった。
図2~5及び下の表1は、遅延放出剤形についての米国薬局方(USP<711>)に従って実施した、プロトタイプ製剤1~4を含有するカプセルのカプセル溶解試験の結果を示す。
CR845酢酸塩/トレハロース/クエン酸(9.8/88.2/2.2%w/w)及びCR845.HCl/トレハロース(23/77%w/w)のスプレー乾燥粒子を本質的に腸溶性(耐酸性)のHPMCカプセルに充填し、イヌ8匹のコホートに投与した。酢酸塩に添加したクエン酸は、pHを平衡させるためであった。各製剤における平均生物学的利用率を上記のように判定し、下の表2に示した。
サイズ1のLiCap(Capsugel)の腸溶コーティングカプセル中の製剤5、6及び7をそれぞれ8kgのイヌ8匹のコホートに投与した。製剤5は、4.0mgのCR845.HCl、Miglyol(登録商標)812N中の20%カプリン酸を含有し;製剤6は、4.0mgのCR845.HCl、Miglyol(登録商標)812N中の10%カプリン酸を含有し;製剤7は、4.0mgのCR845.HCl、Miglyol(登録商標)812N中の5%カプリン酸を含有した。
第1サンプル試験では、トレハロース中に包埋された2.5mgのCR845のスプレー乾燥粒子を1gmのMiglyol(登録商標)(A)又はMiglyol(登録商標)中の10%カプリン酸(B)に懸濁した。別のサンプル試験では、トレハロース/Naカプリン酸塩/EDTA中に包埋された2.5mgのCR845のスプレー乾燥粒子を1gmのMiglyol(登録商標)(C)又はMiglyol(登録商標)中の10%カプリン酸(D)に懸濁した。室温で調製した懸濁液をCR845の含量及び純度についてアッセイした。次に、懸濁液を、安定性を評価するため、40℃、75%相対湿度で貯蔵し、2か月後及び3か月後に再びアッセイした。
製剤8~12の生物活性を上記のように判定した。製剤の組成物を下の表5に示す。
Claims (15)
- κオピオイド受容体作動薬の経口送達のための製剤であって、前記κオピオイド受容体作動薬及び吸収促進剤を含み、前記吸収促進剤は、
(a)中鎖脂肪酸又は中鎖脂肪酸の塩;
(b)中鎖脂肪酸グリセリド;又は
(c)(i)中鎖脂肪酸又は中鎖脂肪酸の塩、及び
(ii)中鎖脂肪酸グリセリド
を含む、製剤。 - 前記中鎖脂肪酸は、カプリン酸及び/又はカプリン酸塩を含む、請求項1に記載の製剤。
- 前記中鎖脂肪酸グリセリドは、中鎖脂肪酸トリグリセリドを含む、請求項1に記載の製剤。
- 前記中鎖トリグリセリドは、Miglyol(登録商標)810、Miglyol(登録商標)812、Capmul(登録商標)MCM、Captex(登録商標)100、Captex(登録商標)200、Captex(登録商標)300、Captex(登録商標)355、Neobee(登録商標)1053、Neobee(登録商標)M5及びCapmul(登録商標)PGMCからなる群から選択される、請求項4に記載の製剤。
- 薬学的に許容できる希釈剤、賦形剤又は担体をさらに含む、請求項2に記載の製剤。
- 治療薬の経口送達のための製剤を含有するカプセルであって、前記製剤は、κオピオイド受容体作動薬及び吸収促進剤を含み、前記吸収促進剤は、中鎖脂肪酸又は中鎖脂肪酸の塩;及び中鎖脂肪酸グリセリドを含み、前記カプセルは、腸溶コーティングカプセル又は固有の腸溶特性を有するカプセルである、カプセル。
- 安定化されたκオピオイド受容体作動薬を含む粒子を形成する、1つ以上のグルコース単量体を含むオリゴマー糖中に包埋されたκオピオイド受容体作動薬を含む生理活性組成物。
- 前記κオピオイド受容体作動薬は、CR845を含み、且つ前記オリゴマー糖は、トレハロースを含む、請求項8に記載の生理活性組成物。
- カルボン酸の塩、吸収促進剤、結合剤、キレート剤及び薬学的に許容できる担体又は賦形剤の1つ以上をさらに含む、請求項9に記載の生理活性組成物。
- 前記カルボン酸の前記塩は、クエン酸ナトリウムを含み、前記キレート剤は、EDTAを含み、且つ前記吸収促進剤は、ラウロイルL-カルニチンを含む、請求項10に記載の生理活性組成物。
- 1つ以上の中鎖脂肪酸又は中鎖脂肪酸の1つ以上の塩及び中鎖脂肪酸グリセリドをさらに含む、請求項9に記載の生理活性組成物。
- 請求項9に記載の生理活性組成物を含む薬学的に許容できる錠剤、カプレット、カプセル、散剤又は懸濁液。
- 前記懸濁液は、吸収促進剤及び薬学的に許容できる(C8~C12)短鎖脂肪酸トリグリセリドの1つ以上をさらに含む、請求項13に記載の生理活性組成物。
- 乳化剤、カルボン酸の塩、吸収促進剤、結合剤及び薬学的に許容できる担体又は賦形剤の1つ以上をさらに含む、請求項14に記載の生理活性組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862731802P | 2018-09-14 | 2018-09-14 | |
US62/731,802 | 2018-09-14 | ||
PCT/US2019/051002 WO2020056249A1 (en) | 2018-09-14 | 2019-09-13 | Oral formulations of kappa opioid receptor agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022513556A true JP2022513556A (ja) | 2022-02-09 |
JP7280350B2 JP7280350B2 (ja) | 2023-05-23 |
Family
ID=69774717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021513853A Active JP7280350B2 (ja) | 2018-09-14 | 2019-09-13 | κオピオイド受容体作動薬の経口製剤 |
Country Status (15)
Country | Link |
---|---|
US (3) | US11033629B2 (ja) |
EP (1) | EP3849579A4 (ja) |
JP (1) | JP7280350B2 (ja) |
KR (1) | KR102664288B1 (ja) |
CN (1) | CN112739366A (ja) |
AU (1) | AU2019337671A1 (ja) |
BR (1) | BR112021004461A2 (ja) |
CA (1) | CA3112477C (ja) |
IL (1) | IL281393A (ja) |
MX (1) | MX2021002892A (ja) |
MY (1) | MY196513A (ja) |
PH (1) | PH12021550537A1 (ja) |
SG (1) | SG11202102504WA (ja) |
WO (1) | WO2020056249A1 (ja) |
ZA (1) | ZA202102263B (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY196513A (en) * | 2018-09-14 | 2023-04-18 | Cara Therapeutics Inc | Oral Formulations of Kappa Opioid Receptor Agonists |
US11986509B2 (en) * | 2020-03-18 | 2024-05-21 | Cara Therapeutics, Inc. | Oligosaccharide formulations of kappa opioid receptor agonists |
KR20230024419A (ko) | 2020-06-25 | 2023-02-20 | 휴먼웰 파마슈티컬 유에스 | 의학적 장애 치료용 펩티드 |
CN115043904A (zh) * | 2021-03-08 | 2022-09-13 | 成都奥达生物科技有限公司 | 一种长效k阿片受体激动剂 |
WO2022198129A1 (en) * | 2021-03-19 | 2022-09-22 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Use of kappa opioid receptor agonists to treat cardiovascular disease |
WO2023161938A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of kappa opioid receptor agonist peptide |
US20230285497A1 (en) * | 2022-03-11 | 2023-09-14 | Cara Therapeutics, Inc. | Atopic dermatitis therapy with kappa opioid receptor agonist as adjunct to topical corticosteroid |
WO2024015106A1 (en) * | 2022-07-11 | 2024-01-18 | Humanwell Pharmacuetical Us | Peptides for treatment of medical disorders |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5804557A (en) * | 1993-02-23 | 1998-09-08 | Genentech, Inc. | Excipient stabilization of polypeptides treated with organic solvents |
US6187330B1 (en) * | 1998-01-30 | 2001-02-13 | Scios Inc. | Controlled release delivery of peptide or protein |
US8217007B1 (en) * | 2006-11-10 | 2012-07-10 | Cara Therapeutics, Inc. | Synthetic peptide amides |
US20150150935A1 (en) * | 2012-06-05 | 2015-06-04 | Cara Therapeutics, Inc. | Peripheral kappa receptor agonists for reducing pain and inflammation |
JP2015168630A (ja) * | 2014-03-05 | 2015-09-28 | 東海カプセル株式会社 | カプセル充填組成物 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
US20180078605A1 (en) * | 2006-11-10 | 2018-03-22 | Cara Therapeutics, Inc. | Peripheral kappa opioid receptor agonists for uremic pruritus in dialysis patients |
WO2008064353A2 (en) * | 2006-11-22 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | 7,8-saturated-4,5-epoxy-morphinanium analogs |
AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
FR2963889B1 (fr) * | 2010-08-20 | 2013-04-12 | Debregeas Et Associes Pharma | Formulations a base de nalbuphine et leurs utilisations |
US8697644B2 (en) | 2011-03-10 | 2014-04-15 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of peptide drugs |
US10028916B2 (en) * | 2014-05-16 | 2018-07-24 | Vivus, Inc. | Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use |
DK3199175T3 (da) | 2014-09-27 | 2022-06-13 | Sumitomo Pharma Co Ltd | Farmaceutisk sammensætning til injektion |
US20190111001A1 (en) | 2016-03-30 | 2019-04-18 | University Of Maryland, Baltimore | Microparticulate system for colonic drug delivery |
MY196513A (en) * | 2018-09-14 | 2023-04-18 | Cara Therapeutics Inc | Oral Formulations of Kappa Opioid Receptor Agonists |
-
2019
- 2019-09-13 MY MYPI2021001301A patent/MY196513A/en unknown
- 2019-09-13 BR BR112021004461-2A patent/BR112021004461A2/pt unknown
- 2019-09-13 EP EP19942617.2A patent/EP3849579A4/en active Pending
- 2019-09-13 CA CA3112477A patent/CA3112477C/en active Active
- 2019-09-13 MX MX2021002892A patent/MX2021002892A/es unknown
- 2019-09-13 SG SG11202102504WA patent/SG11202102504WA/en unknown
- 2019-09-13 US US16/570,333 patent/US11033629B2/en active Active
- 2019-09-13 CN CN201980059966.3A patent/CN112739366A/zh active Pending
- 2019-09-13 JP JP2021513853A patent/JP7280350B2/ja active Active
- 2019-09-13 WO PCT/US2019/051002 patent/WO2020056249A1/en unknown
- 2019-09-13 KR KR1020217010763A patent/KR102664288B1/ko active IP Right Grant
- 2019-09-13 AU AU2019337671A patent/AU2019337671A1/en active Pending
-
2021
- 2021-03-10 IL IL281393A patent/IL281393A/en unknown
- 2021-03-11 PH PH12021550537A patent/PH12021550537A1/en unknown
- 2021-04-06 ZA ZA2021/02263A patent/ZA202102263B/en unknown
- 2021-04-28 US US17/242,678 patent/US11684674B2/en active Active
-
2023
- 2023-06-20 US US18/211,787 patent/US20230338546A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5804557A (en) * | 1993-02-23 | 1998-09-08 | Genentech, Inc. | Excipient stabilization of polypeptides treated with organic solvents |
US6187330B1 (en) * | 1998-01-30 | 2001-02-13 | Scios Inc. | Controlled release delivery of peptide or protein |
US8217007B1 (en) * | 2006-11-10 | 2012-07-10 | Cara Therapeutics, Inc. | Synthetic peptide amides |
US20150150935A1 (en) * | 2012-06-05 | 2015-06-04 | Cara Therapeutics, Inc. | Peripheral kappa receptor agonists for reducing pain and inflammation |
JP2015168630A (ja) * | 2014-03-05 | 2015-09-28 | 東海カプセル株式会社 | カプセル充填組成物 |
Non-Patent Citations (1)
Title |
---|
ADVANCED DRUG DELIVERY REVIEWS, vol. 106, JPN6022038325, 2016, pages 277 - 319, ISSN: 0004980229 * |
Also Published As
Publication number | Publication date |
---|---|
CA3112477A1 (en) | 2020-03-19 |
US20210346505A1 (en) | 2021-11-11 |
CA3112477C (en) | 2023-10-03 |
MY196513A (en) | 2023-04-18 |
IL281393A (en) | 2021-04-29 |
US20230338546A1 (en) | 2023-10-26 |
SG11202102504WA (en) | 2021-04-29 |
PH12021550537A1 (en) | 2022-02-21 |
KR102664288B1 (ko) | 2024-05-09 |
EP3849579A1 (en) | 2021-07-21 |
JP7280350B2 (ja) | 2023-05-23 |
US20200085961A1 (en) | 2020-03-19 |
MX2021002892A (es) | 2021-08-24 |
BR112021004461A2 (pt) | 2021-05-25 |
US11033629B2 (en) | 2021-06-15 |
AU2019337671A1 (en) | 2021-05-13 |
ZA202102263B (en) | 2022-08-31 |
KR20210057132A (ko) | 2021-05-20 |
US11684674B2 (en) | 2023-06-27 |
CN112739366A (zh) | 2021-04-30 |
WO2020056249A1 (en) | 2020-03-19 |
EP3849579A4 (en) | 2022-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022513556A (ja) | κオピオイド受容体作動薬の経口製剤 | |
TWI801373B (zh) | 胜肽化合物 | |
JP6220180B2 (ja) | 合成ペプチドアミドおよびその二量体 | |
CN103764159A (zh) | 芳香族阳离子肽及其用途 | |
ES2398673T3 (es) | Métodos de tratamiento o prevención de la emesis usando secretagogos de hormona de crecimiento | |
ES2532950T3 (es) | Composición farmacéutica con los principios activos metformina y sitagliptina o vildagliptina | |
KR102645633B1 (ko) | 신경학적 장애를 치료하는 방법 | |
HRP20020182A2 (en) | Benzamide formulation with histone deacetylase inhibitor activity | |
JP2014529621A (ja) | 抗炎症性の置換シクロブテンジオン化合物のコリン塩 | |
JP3689104B2 (ja) | 安定な経口用固形医薬組成物 | |
JP2014515747A (ja) | 医薬組成物 | |
JP5678088B2 (ja) | 4−メチルピラゾール製剤 | |
KR101199730B1 (ko) | 병리학적 맥락막 혈관신생과 관련된 질환을 치료하기 위한1,2,3-치환된 인돌리진 유도체의 용도 | |
US20230381265A1 (en) | Oligosaccharide formulations of kappa opioid receptor agonists | |
EP1300155A1 (en) | Enteric preparations containing physiologically active peptides | |
JP2013531026A (ja) | B型ランチビオティックを含む製剤 | |
JP5321454B2 (ja) | 医薬錠剤の製造法 | |
CN108883094A (zh) | 炎症性肠病治疗剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210927 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210927 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220909 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230405 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230502 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230511 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7280350 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |